[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2010105822A3 - Trockenverarbeitung von retigabin - Google Patents

Trockenverarbeitung von retigabin Download PDF

Info

Publication number
WO2010105822A3
WO2010105822A3 PCT/EP2010/001690 EP2010001690W WO2010105822A3 WO 2010105822 A3 WO2010105822 A3 WO 2010105822A3 EP 2010001690 W EP2010001690 W EP 2010001690W WO 2010105822 A3 WO2010105822 A3 WO 2010105822A3
Authority
WO
WIPO (PCT)
Prior art keywords
retigabine
dry processing
relates
finally
dosage forms
Prior art date
Application number
PCT/EP2010/001690
Other languages
English (en)
French (fr)
Other versions
WO2010105822A2 (de
Inventor
Katrin Rimkus
Jana Pätz
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Priority to EA201171140A priority Critical patent/EA201171140A1/ru
Priority to US13/257,056 priority patent/US20120122973A1/en
Priority to EP10711009A priority patent/EP2408424A2/de
Priority to CA2760040A priority patent/CA2760040A1/en
Publication of WO2010105822A2 publication Critical patent/WO2010105822A2/de
Publication of WO2010105822A3 publication Critical patent/WO2010105822A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft Trockenverfahren zur Herstellung von oralen Darreichungsformen, insbesondere Tabletten, enthaltend Retigabin und Adhäsionsverstärker. Ferner betrifft die Erfindung kompaktierte Intermediate, enthaltend Retigabin und einen Adhäsionsvers tärker. Schließlich betrifft die Erfindung Ein- und Mehrdosenbehältnisse, bevorzugt Sachets und Stick-Packs, enthaltend das erfindungsgemäße Intermediat.
PCT/EP2010/001690 2009-03-17 2010-03-17 Trockenverarbeitung von retigabin WO2010105822A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EA201171140A EA201171140A1 (ru) 2009-03-17 2010-03-17 Сухая переработка ретигабина
US13/257,056 US20120122973A1 (en) 2009-03-17 2010-03-17 Dry processing of retigabine
EP10711009A EP2408424A2 (de) 2009-03-17 2010-03-17 Trockenverarbeitung von retigabin
CA2760040A CA2760040A1 (en) 2009-03-17 2010-03-17 Dry-processing of retigabine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009013613A DE102009013613A1 (de) 2009-03-17 2009-03-17 Trockenverarbeitung von Retigabin
DE102009013613.4 2009-03-17

Publications (2)

Publication Number Publication Date
WO2010105822A2 WO2010105822A2 (de) 2010-09-23
WO2010105822A3 true WO2010105822A3 (de) 2011-04-21

Family

ID=42136030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/001690 WO2010105822A2 (de) 2009-03-17 2010-03-17 Trockenverarbeitung von retigabin

Country Status (6)

Country Link
US (1) US20120122973A1 (de)
EP (1) EP2408424A2 (de)
CA (1) CA2760040A1 (de)
DE (2) DE102009013613A1 (de)
EA (1) EA201171140A1 (de)
WO (1) WO2010105822A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787247A1 (en) * 2010-01-20 2011-07-28 Glaxo Group Limited Novel composition
US20130224294A1 (en) 2010-09-28 2013-08-29 Ratiopharm Gmbh Dry processing of atazanavir
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
BR112022010458A2 (pt) * 2019-12-02 2022-09-06 Xenon Pharmaceuticals Inc Formulação pediátrica de liberação imediata do abridor de canais de potássio ezogabina

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066081A2 (de) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
DE20321314U1 (de) * 2002-05-31 2006-10-12 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
WO2010009433A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
WO2010105823A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes retigabin in nicht-kristalliner form
WO2010105824A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-tabletten, bevorzugt mit modifizierter freisetzung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
CA2631233C (en) * 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066081A2 (de) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
DE20321314U1 (de) * 2002-05-31 2006-10-12 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
WO2010009433A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
WO2010105823A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes retigabin in nicht-kristalliner form
WO2010105824A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-tabletten, bevorzugt mit modifizierter freisetzung

Also Published As

Publication number Publication date
CA2760040A1 (en) 2010-09-23
WO2010105822A2 (de) 2010-09-23
EP2408424A2 (de) 2012-01-25
DE202010017303U1 (de) 2011-12-13
US20120122973A1 (en) 2012-05-17
DE102009013613A1 (de) 2010-09-23
EA201171140A1 (ru) 2012-04-30

Similar Documents

Publication Publication Date Title
WO2010105822A3 (de) Trockenverarbeitung von retigabin
EP2529634A4 (de) Portioniertes tabakprodukt
IL213074A0 (en) Capsule for the preparation of a beverage by centrifugation
EP2539102A4 (de) Verfahren zur herstellung von angrenzenden metallbindungen zwischen verschiedenen materialien mit festphasen-bonding und auf diese weise hergestellte produkte
EP2578650A4 (de) Zusammensetzung zur verwendung als beschichtungsmaterial, haftbindungsverfahren und laminierte produkte
WO2011131368A3 (en) A method of preparing an oral dosage form comprising fingolimod
PL2413902T3 (pl) Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne
ZA201304859B (en) Capsule and method for the preparation of a beverage by centrifugation
PL2346806T3 (pl) Sposób wytwarzania witaminy k2
WO2012016683A3 (en) Oral dosage form of pregabalin
EP2532255A4 (de) Orales tabakprodukt
EP2713730A4 (de) Verfahren zur herstellung von saxagliptin und neue zwischenprodukte für dessen synthese
GB201004876D0 (en) Process for the preparation of vitamin K2
SI2539240T1 (sl) Lahek vsebnik enega odmerka
IL219156A0 (en) Process for the preparation of f-series prostaglandins
WO2012142302A3 (en) Biocatalytic process for preparing eslicarbazepine and analogs thereof
SI2536396T1 (sl) Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
GB201001758D0 (en) Improvements relating to the opening of bags, especially bags containing food products
EP2676670A4 (de) Adiponectinproduktionsförderer und medizinische zusammensetzung, nahrungsmittel, getränke und futter mit dem adiponectinproduktionsförderer
EP2648532B8 (de) Zusammengesetztes produkt enthaltend eine füllungszusammensetzung mit hydrolysiertem vollkorn
EP2581621A4 (de) Verfahren zur herstellung von bremsscheiben und bremsscheibe
HK1169832A1 (en) Novel solid materials of [2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)- 8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza- cyclopentadec-2-yl]-acetic acid and methods for obtaining them [(2s5r8s11s)-5--11-(3--)-8--7--36912 15--1471013---2-]-
PL2463117T3 (pl) Konstrukcja obręczy koła z materiału kompozytowego
PL2513289T3 (pl) Bezkartonowy pakunek produktów stałych z drożdży
WO2010084515A3 (en) A process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10711009

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010711009

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201171140

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2760040

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13257056

Country of ref document: US